Thus, it has been considered that low levels or decreased CYP3A4 effectiveness might result in a minor capacity to deactivate testosterone, favoring its conversion to dihydrotestosterone (DHT), and increasing the risk of prostate hypertrophy and hyperplasia, especially over the age of 50, or incrementing prostate cancer development under conditions of intense DHT activity. The gene discussed is CYP3A4; the disease is prostate carcinoma.